Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 54 Week Treatment, Randomized, Multi Center, Double Blind, Placebo Controlled Study to Assess the Safety and Efficacy of NEBIDO [testosterone undecanoate] 1000 mg (4 ml) in Elderly Men With Symptomatic Late Onset Hypogonadism (SLOH).

Next Previous
X
Search
Trial Profile

A 54 Week Treatment, Randomized, Multi Center, Double Blind, Placebo Controlled Study to Assess the Safety and Efficacy of NEBIDO [testosterone undecanoate] 1000 mg (4 ml) in Elderly Men With Symptomatic Late Onset Hypogonadism (SLOH).

Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 09 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Testosterone undecanoate (Primary)
  • Indications Hypogonadism
  • Focus Pharmacodynamics
  • Sponsors Bayer

    • Most Recent Events

    • 16 Nov 2011 Additional locations (England, Italy, Latvia, Poland, Russia, United Kingdom) added as reported by ClinicalTrials.gov.
    • 22 Nov 2010 Trial location (Germany) identified as reported by ClinicalTrials.gov.
    • 22 Nov 2010 Planned end date changed from 1 Oct 2010 to 1 Oct 2008 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top